Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN
| Autor: | Alain Gadisseur, Hendrik De Raeve, Jan Jacques Michiels, Wilfried Schroyens, Potter, Zwi N. Berneman, K. Schelfout, Fransje Valster |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Pathology Myeloid business.industry Essential thrombocythemia Treatment options medicine.disease Gastroenterology 03 medical and health sciences 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Polycythemia vera hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Metaplasia Medicine Bone marrow medicine.symptom business Myelofibrosis Myeloproliferative neoplasm |
| Zdroj: | Journal of Hematology & Thromboembolic Diseases. |
| ISSN: | 2329-8790 |
| DOI: | 10.4172/2329-8790.1000277 |
| Popis: | JAK2V617F PV is a trilinear myeloproliferative neoplasm preceded by erythromelalgic thrombocythemia followed by myeloproliferative myeloid metaplasia of spleen and bone marrow and secondary myelofibrosis. The CALR and MPL mutated JAK2 wild type thrombocythemia complicated by myelofibrosis (MF) and agnogenic myeloid metaplasia (AMM) have no features of polycythemia vera (PV) are not primary or agnogenic anymore. The natural history of CALR and MPL thrombocythemia and secondary bone marrow fibrosis clearly differ fromJAK2V617F trilinear essential thrombocythemia (ET), PV, post-ET and post-PV secondary myelofibrosis. Evolution of anemia, splenomegaly and myelofibrosis in MPL, CALR thrombocythemia and JAK2V617F trilinear thrombocythemia and polycythemia vera (TPV) should be evaluated separately simple because treatment options differ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|